Koru Medical Systems (NASDAQ: KRMD) insider transactions
In the twelve months to 10 November 2026, executives and directors of Koru Medical Systems reported 0 open-market sales and 8 open-market purchases of 61,191 shares ($1.6m), by 5 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 1 October 2026 | Cascella Robert | Director | Grant or award | +5,119 | $2.93 | 103,274 | Form 4 |
| 1 October 2026 | Fletcher R John | Director | Grant or award | +7,679 | $2.93 | 239,836 | Form 4 |
| 1 October 2026 | French Donna | Director | Grant or award | +5,119 | $2.93 | 103,633 | Form 4 |
| 1 October 2026 | Matin Shahriar | Director | Grant or award | +5,119 | $2.93 | 106,263 | Form 4 |
| 1 October 2026 | Wholihan Edward | Director | Grant or award | +5,119 | $2.93 | 56,431 | Form 4 |
| 30 September 2026 | Manko Joseph M. Jr. | Director | Grant or award | +5,119 | — | 5,074,660 | Form 4 |
| 8 September 2026 | Kalbermatten Adam R | Chief Commercial Officer | Open-market purchase | +32,000 | $3.16 | 394,017 | Form 4 |
| 28 July 2026 | Kalbermatten Adam R | Chief Commercial Officer | Option exercise | +75,000 | — | 387,500 | Form 4 |
| 28 July 2026 | Kalbermatten Adam R | Chief Commercial Officer | Shares withheld for tax | −25,483 | $4.26 | 362,017 | Form 4 |
| 1 July 2026 | Cascella Robert | Director | Grant or award | +3,571 | $4.20 | 98,155 | Form 4 |
| 1 July 2026 | Fletcher R John | Director | Grant or award | +5,357 | $4.20 | 232,157 | Form 4 |
| 1 July 2026 | French Donna | Director | Grant or award | +3,571 | $4.20 | 98,514 | Form 4 |
| 1 July 2026 | Matin Shahriar | Director | Grant or award | +3,571 | $4.20 | 101,144 | Form 4 |
| 1 July 2026 | Wholihan Edward | Director | Grant or award | +3,571 | $4.20 | 51,312 | Form 4 |
| 30 June 2026 | Horton Capital Partners, LLC | — | Grant or award | +3,571 | — | 5,069,541 | Form 4 |
| 11 June 2026 | Kalbermatten Adam R | President-Chief Commercial Off | Open-market purchase | +5,000 | $3.96 | 305,000 | Form 4 |
| 11 June 2026 | Kalbermatten Adam R | President-Chief Commercial Off | Open-market purchase | +7,500 | $3.93 | 312,500 | Form 4 |
| 18 May 2026 | Schiller Eric | Chief Technology Officer | Open-market purchase | +5,000 | $3.91 | 5,000 | Form 4 |
| 15 May 2026 | Tharby Linda M | Chief Executive Officer | Open-market purchase | +1,191 | $1,191.00 | 620,622 | Form 4 |
| 14 May 2026 | Tharby Linda M | Chief Executive Officer | Option exercise | +13,977 | — | 626,757 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Koru Medical Systems page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.